摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(p-chlorobenzenesulfonyl)-6-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole

中文名称
——
中文别名
——
英文名称
1-(p-chlorobenzenesulfonyl)-6-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole
英文别名
1-(p-chlorobenzenesulfonyl)-6-methoxy-2-[(3,5-dimethyl-4-methoxy-pyridin-2-yl)methylsulfinyl]-1H-benzimidazole;1-(4-Chlorophenyl)sulfonyl-6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazole
1-(p-chlorobenzenesulfonyl)-6-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole化学式
CAS
——
化学式
C23H22ClN3O5S2
mdl
——
分子量
520.03
InChiKey
DSPCRQZSDPGRRA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    34
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    128
  • 氢给体数:
    0
  • 氢受体数:
    8

文献信息

  • PRODRUGS OF PROTON PUMP INHIBITORS
    申请人:Winston Pharmateuticals LLC
    公开号:EP1105387B1
    公开(公告)日:2003-01-29
  • US6093734A
    申请人:——
    公开号:US6093734A
    公开(公告)日:2000-07-25
  • US6559167B1
    申请人:——
    公开号:US6559167B1
    公开(公告)日:2003-05-06
  • [EN] PRODRUGS OF PROTON PUMP INHIBITORS<br/>[FR] PROMEDICAMENTS D'INHIBITEURS DE LA POMPE A PROTONS
    申请人:PARTNERSHIP OF MICHAEL E GARST
    公开号:WO2000009498A1
    公开(公告)日:2000-02-24
    Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable sulfinyl or arylsulfonyl group attached to the benzimidazole nitrogen, or include a group that forms a Mannich base with the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under physiological conditions to provide the proton pump inhibitors with a half life measurable in hours, and are capable of providing sustained plasma concentrations of the proton pump inhibitor drugs for longer time than presently used drugs. The generation of the proton pump inhibitor drugs from the prodrugs of the invention under physiological conditions allows for more effective treatment of several diseases and conditions caused by gastric acid secretion.
查看更多